Clinical trial
Mifepristone (RU-486) in Androgen Independent Prostate Cancer
NCT00140478 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00140478 |
|---|---|
| Title | Mifepristone (RU-486) in Androgen Independent Prostate Cancer |
| Official title | A Phase II Study of Mifepristone (RU-486) in Androgen Independent Prostate Cancer With Correlative Assessment of Androgen Receptor Co-Repressor Proteins |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Massachusetts General Hospital Brigham and Women's Hospital Georgetown University |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer, Adenocarcinoma of Prostate |
| Intervention type | Drug |
| Interventions | Mifepristone |
| Enrollment | 48 |
| Start date | Feb 1, 2005 |
| Primary completion | Jun 1, 2006 |
| Completion | Jan 1, 2008 |
| First posted | Sep 1, 2005 |
| Last update posted | Dec 9, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: